Cd3 Antigen Inhibitors Pipeline Insight
DelveInsight’s, “CD3 Antigen Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CD3 Antigen Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CD3 Antigen Inhibitors Understanding
CD3 Antigen Inhibitors: Overview
Cluster of differentiation 3 (CD3) is a multimeric protein complex, known historically as the T3 complex, and is composed of four distinct polypeptide chains; epsilon (ε), gamma (γ), delta (δ) and zeta (ζ), that assemble and function as three pairs of dimers (εγ, εδ, ζζ). The CD3 complex serves as a T cell co-receptor that associates noncovalently with the T cell receptor
Function - In immunology, Cluster of differentiation 3 as T-cell co-receptor helps to activate the cytotoxic T-Cell. CD3 consists of a protein complex and is composed of four distinct chains. These chains associate with a molecule known as the T-cell receptor (TCR) and the ζ-chain (zeta-chain) to generate an activation signal in T lymphocytes. The TCR, ζ-chain, and CD3 molecules together constitute the TCR complex. The complex functions to transduce intracellular signals during TCR antigen recognition. CD3 epsilon is one of at least three invariant proteins that associate with the variable antigen recognition chains of the T cell receptor and function in signal transduction.
CD3 Antigen Inhibitors - The CD3 protein complex is an important T cell marker for the classification of malignant lymphomas and leukemias (T cell neoplasms). CD3 can also be used for the identification of T cells in coeliac disease, lymphocytic colitis and collagenous colitis. Animal studies have shown that anti-CD3 antibodies induce tolerance to allografts (Nicolls et al. 1993). OKT3, an anti-CD& antibody directed against CD3 ε, has been clinically approved for use in humans for the induction of immunosuppression in solid organ transplantation for the prevention and treatment of rejection. Interestingly, susceptibility to type I diabetes has been associated with the CD3 ε genetic locus and anti-CD3 antibodies have been shown to ameliorate the symptoms of this and other auto-immune disorders. New anticancer drug treatments are being developed based upon the CD3 (cluster of differentiation 3) T cell co-receptor, with molecules being designed for altering the co-stimulatory signal to help get the T-cell to recognize the cancer cell and become fully activated.
The companies and academics are working to assess challenges and seek opportunities that could influence CD3 Antigen Inhibitors R&D. The therapies under development are focused on novel approaches for CD3 Antigen Inhibitors.
CD3 Antigen Inhibitors Emerging Drugs Chapters
This segment of the CD3 Antigen Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD3 Antigen Inhibitors Emerging Drugs
Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently in phase 3 stage of development.
Cibisatamab is an intravenously administered T-cell bispecific monoclonal antibody, being developed by Roche for the treatment of Non-small cell lung cancer. Currently, it is in phase I/II stage of development.
Further product details are provided in the report……..
CD3 Antigen Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different CD3 Antigen Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on CD3 Antigen Inhibitors
There are approx. 20+ key companies which are developing the CD3 Antigen Inhibitors. The companies which have their CD3 Antigen Inhibitors drug candidates in the most advanced stage, i.e. phase IIIinclude, Immunocore.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
CD3 Antigen Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CD3 Antigen Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD3 Antigen Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD3 Antigen Inhibitors drugs.
CD3 Antigen Inhibitors Report Insights
- CD3 Antigen Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
CD3 Antigen Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing CD3 Antigen Inhibitors drugs?
- How many CD3 Antigen Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for CD3 Antigen Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD3 Antigen Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CD3 Antigen Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?